Carolyn Owen, MD, MDres(UK), FRCPC - Innovations in Relapsed/Refractory CLL/SLL Therapy: Integrating Non-Covalent BTK Inhibitors for Improved Outcomes

Please visit answersincme.com/FJJ860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in hematology and oncology discusses the use of noncovalent BTK inhibitors in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma (R/R CLL/SLL) after at least 2 prior lines of therapy. Upon completion of this activity, participants should be better able to: Understand the rationale for noncovalent BTK inhibitors in relapsed/refractory (R/R) CLL/SLL after ≥2 prior lines of therapy; Evaluate the risk-benefit profiles of approved and emerging noncovalent BTK inhibitors in R/R CLL/SLL after ≥2 prior lines of therapy; and Develop patient-centered strategies with noncovalent BTK inhibitors to optimize outcomes in R/R CLL/SLL.